A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
ConclusionsCombination therapy of relugolix and abiraterone or apalutamide was associated with a favorable safety and tolerability profile consistent with the known profiles of the individual medications. Castration levels of testosterone were maintained after transitioning to relugolix from other ADTs.Clinical Trial RegistrationClinicalTrials.gov identifier: NCT04666129
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Abiraterone Acetate | Cancer | Cancer & Oncology | Clinical Trials | Electrocardiogram | Hormonal Therapy | Hormones | Laboratory Medicine | Oral Cancer | Prostate Cancer | Study